Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis
Philip D. Anderson, Sydika A. McKissic, Monica Logan, Meejeon Roh, Omar E. Franco, Jie Wang, Irina Doubinskaia, Riet van der Meer, Simon W. Hayward, Christine M. Eischen, Isam-Eldin Eltoum, Sarki A. Abdulkadir
Philip D. Anderson, Sydika A. McKissic, Monica Logan, Meejeon Roh, Omar E. Franco, Jie Wang, Irina Doubinskaia, Riet van der Meer, Simon W. Hayward, Christine M. Eischen, Isam-Eldin Eltoum, Sarki A. Abdulkadir
View: Text | PDF
Research Article Oncology

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis

  • Text
  • PDF
Abstract

Cooperativity between oncogenic mutations is recognized as a fundamental feature of malignant transformation, and it may be mediated by synergistic regulation of the expression of pro- and antitumorigenic target genes. However, the mechanisms by which oncogenes and tumor suppressors coregulate downstream targets and pathways remain largely unknown. Here, we used ChIP coupled to massively parallel sequencing (ChIP-seq) and gene expression profiling in mouse prostates to identify direct targets of the tumor suppressor Nkx3.1. Further analysis indicated that a substantial fraction of Nkx3.1 target genes are also direct targets of the oncoprotein Myc. We also showed that Nkx3.1 and Myc bound to and crossregulated shared target genes in mouse and human prostate epithelial cells and that Nkx3.1 could oppose the transcriptional activity of Myc. Furthermore, loss of Nkx3.1 cooperated with concurrent overexpression of Myc to promote prostate cancer in transgenic mice. In human prostate cancer patients, dysregulation of shared NKX3.1/MYC target genes was associated with disease relapse. Our results indicate that NKX3.1 and MYC coregulate prostate tumorigenesis by converging on, and crossregulating, a common set of target genes. We propose that coregulation of target gene expression by oncogenic/tumor suppressor transcription factors may represent a general mechanism underlying the cooperativity of oncogenic mutations during tumorigenesis.

Authors

Philip D. Anderson, Sydika A. McKissic, Monica Logan, Meejeon Roh, Omar E. Franco, Jie Wang, Irina Doubinskaia, Riet van der Meer, Simon W. Hayward, Christine M. Eischen, Isam-Eldin Eltoum, Sarki A. Abdulkadir

×

Figure 7

Loss of Nkx3.1 facilitates MYC-initiated prostate tumorigenesis in transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Nkx3.1 facilitates MYC-initiated prostate tumorigenesis in trans...
(A) Scheme for concurrent overexpression of MYC and deletion of Nkx3.1 in the prostates of transgenic mice. The Z-MYC construct contains a latent human MYC allele under the control of the CMV enhancer/actin promoter. The floxed allele of Nkx3.1 has loxP sites flanking exon 2, which encodes the Nkx3.1 homeodomain. Cre recombinase is under the control of the prostate-specific Probasin promoter (PB-Cre). When Cre is expressed, the MYC gene will be overexpressed and the Nkx3.1 gene will be concurrently deleted. (B) Graph summarizing prostate histology of Nkx3.1/MYC mutant mice. *P < 0.01 for PBCre;Z-MYC;Nkx3.1f/f relative to PBCre;Z-MYC. (C) Histological characterization of prostate lesions in Nkx3.1/MYC mutant mice. H&E-stained sections of 35-week-old mouse prostates. Note high-grade PIN lesions in PBCre;Z-MYC;Nkx3.1f/+ and PBCre;Z-MYC;Nkx3.1f/f mice. Insets show higher magnifications (×40). Arrows denote mitotic figures. Scale bars: 50 μm. (D) Proliferation in mutant mice prostates assessed by phospho-histone H3 staining. *P < 0.05. Error bars represent mean ± SEM. (E) Areas of focal loss of SMA (arrows) in 35-week-old PBCre;Z-MYC;Nkx3.1f/f mice, suggestive of microinvasion. Scale bar: 50 μm. See also Supplemental Figures 6 and 7.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts